SCHEMBL23200342

SCHEMBL23200342

COc1cccc(S(=O)(=O)Nc2ccccc2C(=O)O)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.66
KMT2A Q03164 7/20 0.66
KEAP1 Q14145 2/20 0.65
NFE2L2 Q16236 2/20 0.65
SLC16A3 O15427 1/20 0.62
GAA P10253 2/20 0.62
KDM4E B2RXH2 1/20 0.60
POLB P06746 1/20 0.60
PGR P06401 1/20 0.59
ALDH1A1 P00352 1/20 0.58
HSD17B10 Q99714 1/20 0.58
LMNA P02545 1/20 0.58
GLO1 Q04760 1/20 0.56
SLC40A1 Q9NP59 1/20 0.56
PTGES2 Q9H7Z7 1/20 0.55
TP53 P04637 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
KAT6A Q92794 1/20 0.55
WDR5 P61964 1/20 0.55
PGAM1 P18669 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23200347 0.90 KEAP1 (0.65) MEN1KMT2AKEAP1NFE2L2SLC16A3
SCHEMBL3555853 0.87 KEAP1 (0.56) MEN1KMT2AKEAP1NFE2L2SLC16A3
SCHEMBL12200959 0.86 CYP2C9 (0.61) MEN1KMT2AKEAP1NFE2L2SLC16A3
SCHEMBL3560551 0.85 KEAP1 (0.54) MEN1KMT2AKEAP1NFE2L2SLC16A3
SCHEMBL2477690 0.85 LMNA (0.70) MEN1KMT2AKEAP1NFE2L2SLC16A3
SCHEMBL30486834 0.85 LMNA (0.70) MEN1KMT2AKEAP1NFE2L2SLC16A3
SCHEMBL3557703 0.84 KEAP1 (0.53) MEN1KMT2AKEAP1NFE2L2SLC16A3
SCHEMBL3988508 0.83 METAP2 (0.74) KEAP1NFE2L2SLC16A3KDM4EPGR
SCHEMBL12200777 0.83 FFAR4 (0.64) MEN1KMT2AKEAP1NFE2L2SLC16A3
SCHEMBL6417385 0.82 MEN1 (0.72) MEN1KMT2AGAAKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes PROMEGA CORPORATION (US) 2024-08-20 US disclosed
EP-4140991-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2024-05-15 EP disclosed
EP-4140991-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES Promega Corporation (US) 2023-03-01 EP disclosed
US-20220365086-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORPORATION 2022-11-17 US disclosed
EP-3802514-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2022-08-03 EP disclosed
US-11390599-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes PROMEGA CORPORATION (US) 2022-07-19 US disclosed
EP-3802514-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES Promega Corporation (US) 2021-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220365086-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES LUC7L2, LYPLAL1, GUSB MEN1 2157/4885KMT2A 2984/4885KEAP1 449/4885
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes LUC7L2, LYPLAL1, GUSB MEN1 2157/4885KMT2A 2984/4885KEAP1 449/4885
US-11390599-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes LUC7L2, LYPLAL1, GUSB MEN1 2157/4885KMT2A 2984/4885KEAP1 449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.